In particular, loss-of-function mutations impairing the expression of the receptor activator of nuclear factor kappa-Β ligand (RANKL) cytokine or its receptor, RANK, have been reported to cause osteopetrosis in 2% and 4.5% of ARO cases, respectively. Here, TNFRSF11A is linked to osteopetrosis.